Please assess the completion status of the following clinical trial:

Trial Title: A Sequential Treatment Regimen of Cryotherapy and Picato® for the Treatment of Actinic Keratosis on the Face and Scalp

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must be competent to understand the nature of the trial and provide informed consent.~* Subjects with 4 to 8 clinically typical, visible and discrete AKs within a contiguous 25 cm2 treatment area on the face or scalp.~* Subject at least 18 years of age.~* Female subjects must be of either:~  * Non-childbearing potential, i.e. post-menopausal or have a confirmed clinical history of sterility (e.g. the subject is without a uterus) or,~ * Childbearing potential, provided there is a confirmed negative urine pregnancy test prior to study treatment, to rule out pregnancy.~* Female subjects of childbearing potential must be willing to use effective contraception.~Exclusion Criteria:~* Location of the selected treatment area:~  * on any location other than the face or scalp~ * within 5 cm of an incompletely healed wound~ * within 10 cm of a suspected basal cell carcinoma (BCC) or SCC~* Prior treatment with PEP005 Gel on face or scalp.~* Selected treatment area lesions that have:~  * atypical clinical appearance and/or~ * recalcitrant disease~* History or evidence of skin conditions other than the trial indication that would interfere with evaluation of the trial medication~* Clinical diagnosis/history or evidence of any medical condition that would expose a subject to an undue risk of a significant AE or interfere with assessments of safety and efficacy.~* Any abnormal vital signs measurements that are medically significant or would impact the safety of the subject or the interpretation of the trial results.~* Anticipated need for hospitalization or out-patient surgery during the first 15 days after the first trial medication application.~* Known sensitivity or allergy to any of the ingredients in PEP005 Gel~* Recent excessive exposure to ultraviolet light~* Current enrolment or participation in a clinical trial within 30 days of entry into this study~* Subjects previously randomised in the trial~* Female subjects who are breastfeeding~Prohibited Therapies and/or Medications within 2 weeks prior to Visit 1~* Cosmetic or therapeutic procedures within 2 cm of the selected treatment area~* Use of acid-containing therapeutic products within 2 cm of the selected treatment area~* Use of topical medicated creams, ointments, lotions, gels, foams or sprays~Prohibited Therapies and/or Medications: within 4 weeks prior to visit 1:~* Treatment with immunomodulators, cytotoxic drugs or inter-feron /interferon inducers~* Treatment with systemic medications that suppress the immune system~* Treatment/therapy with ultraviolet light A (UVA) or ultraviolet light B (UVB).~Prohibited Therapies and/or Medications within 8 weeks prior to visit 1:~* Treatment with 5-FU, imiquimod, diclofenac sodium, or photodynamic therapy: within 2 cm of the selected treatment area.~Prohibited Therapies and/or Medications within 6 months prior to visit 1~* Use of systemic retinoids or biologic / mono-clonal antibody therapies

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PEP005 Gel, 0.015% (Type: ACTIVE_COMPARATOR): Cryotherapy followed by PEP005 Gel, 0.015%
- Vehicle gel (Type: PLACEBO_COMPARATOR): Cryotherapy followed by vehicle gel

Based on this trial design, predict the completion outcome and termination type (if applicable).